



January 23, 2019
JCR Pharmaceuticals Co., Ltd.

Translation

JCR to Present at the 15th Annual *WORLDSymposium™* 2019

JCR Pharmaceuticals Co., Ltd. (TSE: 4552; Chairman and President Shin Ashida; “JCR”) announced that it will give a poster presentation on the non-clinical evaluation of JR-171. JR-171 is a blood-brain barrier (BBB)-penetrating acid alpha-L iduronidase product candidate for the treatment of patients with Hurler syndrome, to which J-Brain Cargo[®], JCR’s proprietary BBB technology, is applied. The poster presentation will be held at the 15th Annual *WORLDSymposium™* 2019* in Orlando, Florida (February 4-8, 2019).

Title	Presented on
Non-clinical evaluation of a blood-brain barrier-penetrating enzyme for the treatment of Mucopolysaccharidosis I	February 5 th 16:30-18:30 EST

* *WORLDSymposium™* is an international symposium held annually in the United States with a focus on basic research to clinical application in the lysosomal diseases.

<http://www.worldsymposia.org/>

[About JCR Pharmaceuticals]

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

END

###